ArticleEJHaem2026

Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study.

Sebastian Grosicki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.